Moderna, Inc. MRNA

AI demand, stronger growth targets and index inclusion fuel a standout month for the enterprise-storage company.

Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.

Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.

Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.

Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.

After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.

Moderna’s stock has been flying high lately. That has one group of analysts saying it’s time to sell.

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S

Today, Sept. 30, 2026, softer PCE growth is supporting sentiment amid heightened single-stock volatility.

Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.

Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

Here's the market action in the first few minutes of trading.

Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.